BioMarin Pharmaceuticals
BMRN
511 hedge funds and large institutions have $13.6B invested in BioMarin Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 193 increasing their positions, 168 reducing their positions, and 57 closing their positions.
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
15% more repeat investments, than reductions
Existing positions increased: 193 | Existing positions reduced: 168
0.47% less ownership
Funds ownership: 96.72% → 96.25% (-0.47%)
3% less funds holding
Funds holding: 529 → 511 (-18)
8% less capital invested
Capital invested by funds: $14.7B → $13.6B (-$1.11B)
18% less first-time investments, than exits
New positions opened: 47 | Existing positions closed: 57
45% less call options, than puts
Call options by funds: $80.7M | Put options by funds: $146M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$191M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$90.7M |
| 3 |
Millennium Management
New York
|
+$63.7M |
| 4 |
Dodge & Cox
San Francisco,
California
|
+$56.5M |
| 5 |
FWIA
Fort Washington Investment Advisors
Cincinnati,
Ohio
|
+$46.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$350M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$75.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$71.9M |
| 4 |
JP Morgan Chase
New York
|
-$65.2M |
| 5 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
-$48.9M |
BMRN Hedge Fund Activity: Q3 2021 in Review
511 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q3 2021, worth a combined $13.6B — down 7.5% from $14.7B a quarter earlier.
Sellers outnumbered buyers: 57 funds closed out of BMRN and 47 opened new positions — a net loss of 10 holders — while 168 trimmed existing stakes and 193 added.
The largest buyer was BlackRock, adding an estimated $191M. The largest seller was Capital Research Global Investors, cutting an estimated $350M.
- 511 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q3 2021, down from 529 in Q2 2021.
- Funds reported $13.6B of BioMarin Pharmaceuticals stock for Q3 2021, down 7.5% quarter-over-quarter.
- 47 funds opened new BioMarin Pharmaceuticals positions in Q3 2021 and 57 closed out, a net change of -10 holders.
- The largest BioMarin Pharmaceuticals buyer in Q3 2021 was BlackRock, an estimated $191M added.
- The largest BioMarin Pharmaceuticals seller in Q3 2021 was Capital Research Global Investors, an estimated $350M sold.
Based on aggregated 13F filings for Q3 2021.